CME REVIEW ARTICLE
Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis

https://doi.org/10.1016/S1081-1206(10)60789-2Get rights and content

Objective

To review the current pathophysiologic mechanisms and recent therapeutic trends in Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).

Data Sources

A MEDLINE search for SJS and TEN in combination with Fas, Fas ligand (FasL), cytotoxic T cells, intravenous immunoglobulin, and cyclosporine for articles published in English during 1966 to 2006.

Study Selection

Information was derived from original research articles and reviews published in peer-reviewed journals.

Results

The hallmark of SJS and TEN is epidermal cell apoptosis, which may be mediated through keratinocyte Fas-FasL interaction or through cytotoxic T-cell release of perforin and granzyme B. Whereas systemic corticosteroid therapy showed contradictory results, intravenous immunoglobulin (IVIG) and cyclosporine have shown promising outcomes. IVIG contains anti-Fas antibodies that can abrogate apoptosis when preincubated with keratinocytes. Most studies on IVIG in SJS and TEN reported improvement in arresting disease progression and reduction in time to skin healing. Because of variations among studies, the findings cannot be optimally compared. In general, mortality varied from 0% to 12% in studies that supported the use of IVIG and 25% to 41.7% in those that did not demonstrate a beneficial effect. Cyclosporine inhibits CD8 activation and thus may reduce epidermal destruction. Relatively few case reports and 1 case series have been published regarding the use of cyclosporine in SJS and TEN. In general, cyclosporine was associated with a significant improvement in time to disease arrest and to complete reepithelization, with no reported fatalities.

Conclusions

Both IVIG and cyclosporine have been associated with enhanced healing and better survival through inhibition of apoptosis. Multicenter, randomized, placebo-controlled trials using a standardized design are needed to validate these findings.

REFERENCES (70)

  • C Mayorga et al.

    Improvement of toxic epidermal necrolysis after the early administration of a single high dose of intravenous immunoglobulin

    Ann Allergy Asthma Immunol

    (2003)
  • M Lissia et al.

    Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report

    Br J Plast Surg

    (2005)
  • M Nasser et al.

    Intravenous immunoglobulin for treatment of toxic epidermal necrolysis

    Am J Med Sci

    (2005)
  • C Ekberg et al.

    Human polyspecific immunoglobulin for therapeutic use induces p21/WAF-1 and Bcl-2, which may be responsible for G1 arrest and long-term survival

    Hum Immunol

    (2001)
  • P Tristani-Firouzi et al.

    Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children

    J Am Acad Dermatol

    (2002)
  • J Szepietowski et al.

    Toxic epidermal necrolysis successfully treated with cyclosporin: report of three cases

    J Eur Acad Dermatol and Venereol

    (1997)
  • P Paquet et al.

    Novel treatments for drug-induced toxic epidermal necrolysis (Lyell's syndrome)

    Int Arch Allergy Immunol

    (2005)
  • LE Bottinger et al.

    Drug induced febrile mucocutaneous syndrome

    Acta Med Scand

    (1975)
  • L Naldi et al.

    Incidence of toxic epidermal necrolysis in Italy

    Arch Dermatol

    (1990)
  • E Schopf et al.

    Toxic epidermal necrolysis and Stevens-Johnson syndrome: an epidemiologic study from West Germany

    Arch Dermatol

    (1991)
  • BL Strom et al.

    A population-based study of Stevens-Johnson syndrome: incidence and antecedent drug exposure

    Arch Dermatol

    (1991)
  • V Leehutaphong et al.

    Stevens-Johnson syndrome and toxic epidermal necrolysis in Thailand

    Int J Dermatol

    (1993)
  • JC Roujeau et al.

    Severe adverse cutaneous reactions to drugs

    N Engl J Med

    (1994)
  • JC Roujeau et al.

    Toxic epidermal necrolysis (Lyell syndrome): incidence and drug etiology in France, 1981 – 1985

    Arch Dermatol

    (1990)
  • JM Parsons

    Management of toxic epidermal necrolysis

    Cutis

    (1985)
  • EF Sheretz et al.

    Phenytoin hypersensitivity reaction presenting with toxic epidermal necrolysis and severe hepatitis

    J Am Acad Dermatol

    (1985)
  • R Patterson et al.

    Effectiveness of early therapy with corticosteroids in Stevens-Johnson syndrome: experience with 41 cases and a hypothesis regarding pathogenesis

    Ann Allergy

    (1994)
  • PS Kim et al.

    Stevens-Johnson syndrome and toxic epidermal necrolysis: a pathophysiologic review with recommendations for a treatment protocol

    J Burn Care Rehabil

    (1983)
  • PH Halebian et al.

    Improved burn center survival of patients with toxic epidermal necrolysis managed with corticosteroids

    Ann Surg

    (1986)
  • C Paul et al.

    Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis

    Br J Dermatol

    (1996)
  • I Viard et al.

    Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin

    Science

    (1998)
  • P Paquet et al.

    Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis

    Arch Dermatol

    (1994)
  • P Paquet et al.

    Keratinocyte injury in drug-induced toxic epidermal necrolysis: simultaneous but distinct topographic expression of CD95R and calprotectin

    Int J Mol Med

    (2002)
  • C Berthou et al.

    Acquisition of granzyme B and Fas ligand proteins by human keratinocytes contributes to epidermal cell defense

    J Immunol

    (1997)
  • B Schnyder et al.

    T-cell mediated cytotoxicity against keratinocytes in sulfamethoxazole-induced skin reaction

    Clin Exp Allergy

    (1998)

    • Cited by (0)

    View full text
    Copyright © 2006 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.